Please select the option that best describes you:

Are you offering durvalumab to patients with Stage III NSCLC with known targeted mutations (ie ALK, EGFR, ROS1, BRAF) after completion of chemoradiation per PACIFIC?   

Answer from: Medical Oncologist at Community Practice
Medical Oncologist at Virginia Cancer Specialists
With even lower numbers of patients with ALK gene ...
Medical Oncologist at The Oncology Institute of Hope and Innovation
I am curious about this too. Any opinions or comme...
Sign in or Register to read more

Answer from: Medical Oncologist at Academic Institution